.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Global Outlook on Advanced Nonsquamous NSCLC

EP. 1: Upfront Immunotherapy for NSCLC

October 17th 2017

EP. 2: Reliability of PD-L1 Testing in NSCLC

October 17th 2017

EP. 3: NSCLC: Approach for Progression on Chemotherapy

October 17th 2017

EP. 4: Duration of Immunotherapy for NSCLC

October 17th 2017

EP. 5: NSCLC: Immunotherapy Beyond Progression

October 17th 2017

EP. 6: Osimertinib as Frontline Therapy for EGFR-Positive NSCLC

October 17th 2017

EP. 7: Managing CNS Metastases in EGFR-Positive NSCLC

October 17th 2017

EP. 8: EGFR-Positive NSCLC: Treatment at Progression

October 17th 2017

EP. 9: Upfront Therapy for ALK/ROS1-Rearranged NSCLC

October 17th 2017

EP. 10: ALEX Trial: Frontline Therapy for ALK-Rearranged NSCLC

October 17th 2017

EP. 11: Second-Line Brigatinib for ALK-Rearranged NSCLC

October 17th 2017

EP. 12: Changing Treatment Paradigm for BRAF-Mutant NSCLC

October 17th 2017

EP. 13: NSCLC: Promising Molecular Targets

October 17th 2017

EP. 14: Consolidation Immunotherapy for Locally Advanced NSCLC

October 17th 2017

EP. 15: Emerging Therapies for Nonsquamous NSCLC

October 17th 2017